Dose-Related Psychotic Symptoms in Chronic Methamphetamine Users

Evidence From a Prospective Longitudinal Study

Rebecca McKetin, PhD; Dan I. Lubman, PhD, FRANZCP, FACHAM; Amanda L. Baker, PhD; Sharon Dawe, PhD; Robert L. Ali, FACHAM, FFPHM

Context: Methamphetamine is associated with psychotic phenomena, but it is not clear to what extent this relationship is due to premorbid psychosis among people who use the drug.

Objective: To determine the change in the probability of psychotic symptoms occurring during periods of methamphetamine use.

Design: Longitudinal prospective cohort study. A fixed-effects analysis of longitudinal panel data, consisting of 4 noncontiguous 1-month observation periods, was used to examine the relationship between changes in methamphetamine use and the risk of experiencing psychotic symptoms within individuals over time.

Setting: Sydney and Brisbane, Australia.

Participants: A total of 278 participants 16 years of age or older who met DSM-IV criteria for methamphetamine dependence on entry to the study but who did not meet DSM-IV criteria for lifetime schizophrenia or mania.

Main Outcome Measures: Clinically significant psychotic symptoms in the past month, defined as a score of 4 or more on any of the Brief Psychiatric Rating Scale items of suspiciousness, hallucinations, or unusual thought content. The number of days of methamphetamine use in the past month was assessed using the Opiate Treatment Index.

Results: There was a 5-fold increase in the likelihood of psychotic symptoms during periods of methamphetamine use relative to periods of no use (odds ratio [OR], 5.3 [95% CI, 3.4-8.3]; P < .001), this increase being strongly dose-dependent (1-15 days of methamphetamine use vs abstinence in the past month: OR, 4.0 [95% CI, 2.5-6.5]; ≥16 days of methamphetamine use vs abstinence in the past month: OR, 11.2 [95% CI, 5.9-21.1]). Frequent cannabis and/or alcohol use (≥16 days of use in the past month) further increased the odds of psychotic symptoms (cannabis: OR, 2.0 [95% CI, 1.1-3.5]; alcohol: OR, 2.1 [95% CI, 1.1-4.2]).

Conclusions: There was a large dose-dependent increase in the occurrence of psychotic symptoms during periods of methamphetamine use among users of the drug.

Published online January 9, 2013.
men\textsuperscript{11,12} and individuals with comorbid risk factors for psychosis (eg, a history of mental disorders and adverse life events\textsuperscript{13-16}). Given that surprisingly high rates of psychotic phenomena have been reported even in general population samples (eg, Kendler et al\textsuperscript{17} found that 28\% of the US general population endorsed 1 or more psychotic symptoms on a psychosis screening instrument, and, using a similar approach, Scott et al\textsuperscript{18} found that 11\% of Australians endorsed at least 1 psychotic symptom), it is important to understand to what extent psychotic symptoms among methamphetamine users are attributable to the drug compared with other risk factors for experiencing psychosis that occur in this population.

The application of so-called fixed-effects analysis to longitudinal data sets can overcome confounding by pre-morbid factors. This type of analysis examines the likelihood of an event (eg, psychotic symptoms) during periods when an individual is exposed to a risk factor (eg, methamphetamine use) relative to when they are not exposed to that risk factor. Examining changes within individuals over time eliminates confounding by pre-existing individual characteristics and other "time-invariant" factors (eg, heritable traits, personality, age, sex, and prior adverse life events). Factors that vary over time (eg, changes in other drug use that co-occur with psychotic symptoms) need to be adjusted for, as in any conventional regression analysis. Fixed-effects analysis is commonly applied within the economics literature, and to a lesser extent within public health research, to strengthen the argument for causal attribution.\textsuperscript{19,20}

The aim of the present study was to better understand the causal contribution of methamphetamine use to psychotic symptoms by applying fixed-effects analysis to longitudinal panel data from a prospective cohort of methamphetamine users.\textsuperscript{21} The relationship between methamphetamine use and psychotic symptoms was assessed over 4 discrete noncontiguous 1-month periods, while adjusting for concurrent changes in other drug use.

**METHOD**

**PARTICIPANTS AND PROCEDURE**

A total of 278 participants met DSM-IV criteria for methamphetamine dependence on entry to the study, and none met DSM-IV criteria for lifetime schizophrenia or mania. DSM-IV diagnoses were assessed using the Composite International Diagnostic Interview.\textsuperscript{22} Participants were selected from a larger cohort, the Methamphetamine Treatment Evaluation Study (MATES) cohort, which is detailed elsewhere.\textsuperscript{21} In brief, the MATES cohort included 400 people entering community-based drug treatment services in Sydney and Brisbane, Australia, for methamphetamine use, and 101 methamphetamine users from Sydney who were not in treatment (ie, recruited through needle and syringe programs and outreach services) but who screened positive for dependence on methamphetamine. Other inclusion criteria for MATES were being at least 16 years old, a comprehension of English, being willing to participate in follow-up interviews, and not having been in methamphetamine treatment, other impatient drug treatment, or in prison, in the month prior to entering the study. These latter exclusion criteria were necessary in MATES to obtain a naturalistic baseline measure of drug use.

From the MATES cohort, 17 participants were excluded because they did not meet DSM-IV criteria for methamphetamine dependence on recruitment. A further 59 participants were excluded because they met DSM-IV criteria for either lifetime schizophrenia or a lifetime manic episode, and 138 participants were excluded because this diagnostic information was not available (ie, these participants did not partake in the follow-up interviews when diagnoses were made). A further 9 participants were excluded because they had not used methamphetamine during any of the 1-month periods analyzed in the present study.

A structured interview schedule was administered at baseline and at each follow-up (3 months, 1 year, and 3 years after the baseline interview). Recruitment of the cohort took place in 2006 and 2007, and follow-up interviews spanned the period from 2006 to 2010. Interviews were conducted face to face or by phone. All participants provided informed consent, were volunteers, and were reimbursed for their time and travel expenses (up to A$40 per interview). All of the participants in the present study were reinterviewed at 3 and 12 months after entry into the cohort, and 83\% (230 of 278) of participants were interviewed at 3 years. The present study used data on drug use, psychotic symptoms, and health and social functioning in the past month at each of these 4 time points, totaling 1064 months of data for all of the participants combined.

**MEASURES**

**Psychotic Symptoms**

Psychotic symptoms were defined as a score of 4 or greater on any of the Brief Psychiatric Rating Scale items of suspiciousness, unusual thought content, or hallucinations, in the past month. Brief Psychiatric Rating Scale scores of 4 or greater indicate clinically significant or pathological symptom intensity.\textsuperscript{23} This procedure has been used previously to measure the prevalence of psychotic phenomena among methamphetamine users.\textsuperscript{8} Ratings were made by trained interviewers (honors level psychology graduates or an equivalent), and weekly meetings were held to review Brief Psychiatric Rating Scale ratings in order to maintain interrater agreement and avoid rater drift.\textsuperscript{24} A selection of interviews (n=42) were audiotaped and rated by a second interviewer for interrater reliability. Interrater agreement for the definition of psychotic symptoms used in our study was 93\%, yielding a $\kappa$ of 0.86.

**Methamphetamine Use**

The number of days of methamphetamine use in the past 4 weeks was assessed using the Opiate Treatment Index.\textsuperscript{25} Self-reported abstinence from methamphetamine use was confirmed in a subsample of the entire MATES cohort (n=83) using hair analysis, with false reporting of abstinence occurring in only 6\% of cases (detailed elsewhere\textsuperscript{26}). Information on the main route of methamphetamine administration (oral, intranasal, smoked, or intravenous) during the past 4 weeks was also recorded.

**Polydrug Use**

The number of days of use in the past 4 weeks was measured for other drugs, including cannabis, heroin, cocaine, ecstasy, hallucinogens, alcohol, and tobacco.
Health and Social Functioning

Disability from poor physical and mental health in the past month was measured using the Physical and Mental Component Scales of the 12-Item Short Form, respectively. Disability was defined as a score of less than 40 (>1 SD below the normative mean). Current employment status (unemployed, casual/part-time employment, full-time employment, student, or home duties), income (net legitimate income in the past fortnight), and living arrangement (public housing, privately rented dwelling, privately owned dwellings, parent’s home, drug treatment center, boarding house/shelter or refuge, no fixed address, or other) were assessed at each time point. An unstable accommodation was defined as living in a boarding house/shelter or refuge, no fixed address, or “other” (which included caravans, sheds, or temporary accommodation with friends).

DESIGN AND STATISTICAL ANALYSIS

A repeated-measures within-subject design was used to examine the relationship between methamphetamine use and psychotic symptoms over 4 discrete 1-month time points. A fixed-effects logistic regression model was used to determine within-subject variability in how psychotic symptoms changed over time with concurrent changes in methamphetamine use. The main outcome measure was psychotic symptoms in the past month, the main predictor variable was number of days of methamphetamine use in the past month, and other drug use measures (number of days of other drug use in the past month) were treated as covariates. All of the variables used in the analysis were time varying (ie, measured at each 1-month period).

Data were analyzed using Stata Special Edition version 11.2. All tests were 2-sided with significance set at \( P < .05 \).

RESULTS

CHARACTERISTICS OF THE SAMPLE

Participants had a mean (SD) age of 31.7 (8.1) years. The majority were male participants (72%), single (72%), and unemployed (78%). Most were Australian born (89%) and nominated English as their preferred language (96%). They had a median of 10 years of schooling (range, 6-12 years of schooling). 44% had completed a tertiary technical or trade qualification, and 6% had completed a university degree.

All participants met DSM-IV criteria for methamphetamine dependence in the year prior to entering our study; they had used the drug for a mean (SD) of 13.1 (7.9) years, and 83% had injected it. Methamphetamine use occurred during 58% of the observed months. During months of methamphetamine use, participants used the drug on a median of 8 days (range, 1-28 days), and injection was typically their main route of administration (79%, compared with 14% smoking and 6% snorting or swallowing). Other drug use consisted primarily of tobacco (89% of months; median of 28 days of use), cannabis (57% of months; median of 20 days use), and alcohol (62% of months; median of 6 days use), with other drug use being less common.

Psychotic symptoms were present for 25% of the observed months, while 60% of the sample reported psychotic symptoms during at least one of the observed months in the study period. Of those months when psychotic symptoms were present, 71% involved suspiciousness, 35% involved unusual thought content (ie, delusions), and 51% involved hallucinations. Most of these symptoms were in the moderate rather than the severe range on the Brief Psychiatric Rating Scale (ie, scores of 4-5).

RELATIONSHIP BETWEEN PSYCHOTIC SYMPTOMS AND METHAMPHETAMINE USE

Unadjusted analyses showed that psychotic symptoms were more common during periods of methamphetamine use and that there was a strong dose-response effect between number of days of methamphetamine use and psychotic symptoms (Table). Psychotic symptoms were also predicted by other drug use (Table); however, the relationship between methamphetamine use and psychotic symptoms persisted after adjustment for the use of other drugs (model 1 in our Table). After adjusting for only those patterns of other drug use that showed evidence of an association with psychotic symptoms (ie, \( \geq 16 \) days of alcohol and/or cannabis use in the past 4 weeks), we found that methamphetamine use was associated with a 5-fold increase in the odds of experiencing psychotic symptoms (odds ratio [OR], 5.3 [95% CI, 3.4-8.3]; \( P < .001 \)) and that the dose-response effect remained (model 2 in our Table). This final model showed that frequent cannabis use and frequent alcohol use (ie, \( \geq 16 \) days in the past 4 weeks) also increased the odds of experiencing psychotic symptoms.

The predicted probability of psychotic symptoms (based on model 2) is shown in our Figure. In the absence of any methamphetamine use and low levels of cannabis and alcohol use (<16 days), the probability of psychotic symptoms was 7%, and this increased in a dose-response manner to 48% with 16 days or more of methamphetamine use. The addition of frequent cannabis and/or alcohol use (\( \geq 16 \) days) increased the probability of psychotic symptoms to between 61% and 69% (Figure).

We also adjusted for concurrent changes in health and social functioning that co-occurred with psychotic symptoms (ie, unemployment, unstable accommodation, low income, higher levels of psychological distress, and disability from both poor physical health and poor mental health) and found that these factors could not account for the relationship between methamphetamine use and psychotic symptoms: 1-15 days of methamphetamine use vs abstinence resulted in an OR of 2.25 (95% CI, 1.29-3.90) \( P = .004 \); 16 days or more of methamphetamine use vs abstinence resulted in an OR of 3.90 (95% CI, 1.80-8.45) \( P < .001 \).

COMMENT

We found that the likelihood of experiencing psychotic symptoms was 5 times higher during periods of methamphetamine use than during periods of no use, with evidence of a strong dose-response effect. The risk of experiencing psychotic symptoms increased from a low baseline level during months of methamphetamine abstinence (7%) to 48% when participants were heavily using...
methamphetamine (≥16 days of use) and was further elevated with frequent cannabis and/or alcohol use (≥16 days) to between 61% and 69%.

The large increase in the risk of psychotic symptoms occurring during periods of methamphetamine use indicates a need to increase awareness of the drug’s potential effect on mental health. Clinicians need to be vigilant for signs of methamphetamine use among patients who present with psychosis and to appreciate the role that methamphetamine plays in the generation of psychotic symptoms. Methamphetamine intoxication is marked by signs of sympathetic arousal (eg, dilated pupils, increased respiration, and increased blood pressure), hyperactivity, alertness, energy, wakefulness, and euphoria. Common signs of chronic use include anorexia, sleep disturbances, and a labile mood. Improved diagnostic guidelines would be helpful to distinguish between methamphetamine psychosis and schizophrenia because making this differentiation is fraught with difficulties, and current diagnostic criteria are poorly operationalized in diagnostic interview schedules.

There is also a need for further investigation of potential treatments for methamphetamine psychosis. Although existing evidence is insufficient to make clinical recommendations, drug treatment facilities that treat methamphetamine users nonetheless require skilled medical practitioners to prescribe antipsychotic medications and/or sedatives in the event of psychiatric emergencies. Protocols are needed for the emergency psychiatric management of patients presenting with methamphetamine psychosis; however, there is a broader need for the ongoing management of psychotic symptoms among methamphetamine users who seek help from drug treatment detoxification and rehabilitation services.

Given that symptoms of psychosis show a strong temporal relationship with methamphetamine use and are most common during periods of heavy methamphetamine use, there is a good argument for providing methamphetamine treatment as a first-line intervention to reduce rates of psychosis among this population. The evidence base for treating methamphetamine dependence is limited, with the current best evidence in favor of behavioral therapies, such as contingency management and cognitive behav-

Table. Relationship Between Drug Use and Psychotic Symptoms

<table>
<thead>
<tr>
<th>Type of Drug Use</th>
<th>Psychotic Symptoms, No. (%) of months</th>
<th>Unadjusted Effects</th>
<th>Model 1a</th>
<th>Model 2b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (n=791 mo)</td>
<td>Yes (n=273 mo)</td>
<td>OR (95% CI)</td>
<td>Univariate P Value</td>
</tr>
<tr>
<td>Methamphetamine use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No use (reference)</td>
<td>397 (50)</td>
<td>55 (20)</td>
<td>4.8 (3.0-7.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>1-15 d</td>
<td>303 (38)</td>
<td>126 (46)</td>
<td>15.8 (8.6-28.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>16-28 d</td>
<td>91 (12)</td>
<td>92 (34)</td>
<td>2.4 (1.5-4.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Cannabis use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No use (reference)</td>
<td>393 (50)</td>
<td>81 (30)</td>
<td>1.6 (1.0-2.5)</td>
<td>.07</td>
</tr>
<tr>
<td>1-15 d</td>
<td>201 (25)</td>
<td>67 (25)</td>
<td>4.3 (2.2-8.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>16-28 d</td>
<td>197 (25)</td>
<td>125 (46)c</td>
<td>3.4 (2.0-6.0)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Alcohol use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No use (reference)</td>
<td>310 (39)</td>
<td>103 (38)</td>
<td>1.7 (1.0-3.0)</td>
<td>.07</td>
</tr>
<tr>
<td>1-15 d</td>
<td>365 (46)</td>
<td>114 (42)</td>
<td>2.0 (0.8-5.0)</td>
<td>.12</td>
</tr>
<tr>
<td>16-28 d</td>
<td>116 (15)</td>
<td>56 (21)c</td>
<td>3.3 (1.6-5.0)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Tobacco use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ecstasy use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hallucinogen use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cocaine use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heroin use</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: OR, odds ratio.

a Simultaneous regression including all variables
b Simultaneous regression including only those factors that showed evidence of a relationship with psychotic symptoms. Variables with empty cells were not included in the model.
c Percentage does not total 100 owing to rounding error.
d Relative to less than 16 days of use.
chronic heavy alcohol consumption can also cause psy-

tactic symptoms. The present study controlled for changes in poly-
national emphasis on methamphetamine psychosis,2-4 the experimental induc-
tion of psychotic symptoms,40 and the strong dose-

In our study, we were able to demonstrate a clear dose-

Although fixed-effects models eliminate potential con-

Although fixed-effects analysis used in the present

Submitted for Publication: March 2, 2012; final revision received May 15, 2012; accepted July 8, 2012.

Correspondence: Rebecca McKetin, PhD, Centre for Research on Ageing, Health and Well-being, Australian National University, Bldg 63, Eggleston Road, Canberra, Australia 0200 (rebecca.mcketin@anu.edu.au).

Author Contributions: Dr McKetin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conflict of Interest Disclosures: Dr Lubman has provided consultancy advice to Lundbeck and has received travel support and speaker honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, and Lundbeck. Dr Ali has received travel support and speaker honoraria from Reckitt Benckiser Pharmaceuticals.

©2013 American Medical Association. All rights reserved.
Funding/Support: This research was funded by the National Health and Medical Research Council (project grant 350974) and the Australian Government Department of Health and Ageing.

Role of Sponsors: The National Health and Medical Research Council and the Australian Government Department of Health and Ageing, who funded this study, did not participate in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: Data were collected through MATES, conducted by the National Drug and Alcohol Research Centre, University of New South Wales. We thank the project investigators Richard Mattick, Joanne Ross, Jake Najman, and Nicole Lee. We also thank the research officers who assisted in the data collection (Shelley Cogger, Erin Kelly, Kate Hetherington, Grace Ho, Cathie Sammut, Sagari Sarkar, Rachel Sutherland, and Miriam Wyzenbeek), the participating treatment agencies, and the research participants.

REFERENCES

27. Staats Special Edition (for Windows) [computer program]. Version 11.2. College Station, TX: StataCorp; 2012.